Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251117:BIT:1662:0) on November 18, 2025, and is solely responsible for the information contained therein.